{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T08:10:21Z","timestamp":1727079021494},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00482-024-00821-1","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:02:32Z","timestamp":1723640552000},"page":"362-364","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Behandlung der Trigeminusneuralgie: dringend mehr Evidenz ben\u00f6tigt","Treatment of trigeminal neuralgia: more evidence urgently needed"],"prefix":"10.1007","volume":"38","author":[{"given":"Ruth","family":"Ruscheweyh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Gierthm\u00fchlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis M.","family":"Hedderich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Go\u00dfrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-024-00821-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-024-00821-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-024-00821-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T07:04:49Z","timestamp":1727075089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-024-00821-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s00482-024-00821-1","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"type":"print","value":"0932-433X"},{"type":"electronic","value":"1432-2129"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"14 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>R.\u00a0Ruscheweyh<\/b>: A.\u00a0Finanzielle Interessen: Unterst\u00fctzung durch den Innovationsfonds zur Erstellung eines Vollantrags auf dem Gebiet der \u201eneuen Versorgungsformen\u201c.\u00a0\u2013 In den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge oder Advisory Boards sowie Unterst\u00fctzung f\u00fcr Kongressreisen von Novartis, Lilly, Lundbeck, Pfizer und Teva.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin in der Neurologischen Klinik und Poliklinik, Klinikum der LMU M\u00fcnchen; Angestellte bei der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG; Leiterin des Kopfschmerzregisters der DMKG). <b>J.\u00a0Gierthm\u00fchlen<\/b>: A.\u00a0Finanzielle Interessen: Vortragst\u00e4tigkeiten f\u00fcr Weiterbildungsveranstaltungen, die von Lilly GmbH; Novartis; AbbVie; Lundbeck; Insignia; MediSage und Teva organisiert wurden. Reisekostenunterst\u00fctzung von Novartis; Gr\u00fcnenthal; Teva; Lilly GmbH.\u00a0\u2013 Beratungshonorare: Omega Pharma.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte \u00c4rztin am Universit\u00e4tsklinikum Schleswig-Holstein, Campus Kiel, Ober\u00e4rztin Interdisziplin\u00e4re Schmerz- und Palliativambulanz, Akutschmerzdienst. Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie (DGN); Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin (DGAI); Deutsche Schmerzgesellschaft (DGSS); International Association for the Study of Pain (IASP); Complex Regional Pain Syndrome Special Interest Group (CRPS-SIG); Neuropathic Pain Special Interest Group (NeuPSIG); Deutscher Forschungsverbund Neuropathischer Schmerz (DFNS); Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft e.\u202fV. (DMKG), Pr\u00e4sident:in der CRPS-SIG (geteilt mit Janet Bultitude). <b>D.M.\u00a0Hedderich<\/b>: A.\u00a0Finanzielle Interessen: D.\u00a0Hedderich gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Oberarzt, Neuroradiologie, Klinikum rechts der Isar, M\u00fcnchen, TU M\u00fcnchen. <b>G.\u00a0Go\u00dfrau<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung (Novartis).\u00a0\u2013 In den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge oder Advisory Boards sowie Unterst\u00fctzung f\u00fcr Kongressreisen von Novartis; Lilly; Lundbeck; Teva.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin Neurologie und Schmerztherapie im Interdisziplin\u00e4ren Universit\u00e4tsSchmerzCentrum des Universit\u00e4tsklinikums Dresden, TU Dresden; Generalsekret\u00e4rin der DMKG. Mitgliedschaften: DMKG, DGN, DGSS, IHS, IASAT. <b>S.\u00a0Leis<\/b>: A.\u00a0Finanzielle Interessen: Drittmittel: Eli Lilly und Biohaven\/Pfizer, \u201eprincipal investigator\u201c (PI); PMU Salzburg, Research and Innovation Fund.\u00a0\u2013 Vortragshonorare: Arbeitsgemeinschaft Neurologie Salzburg Innergebirg (ANSIG); Eli Lilly; Klinikum F\u00fcrth; Menarini; Neuraxpharm; Novartis; \u00d6sterreichische Gesellschaft f\u00fcr Neurologie (\u00d6GN); \u00d6sterreichische Schmerzgesellschaft (\u00d6SG); AbbVie; Pfizer; Medizin Akademie Organisationsteam.\u00a0\u2013 Kostenerstattung f\u00fcr Kongressteilnahme: Fortbildungsfonds Uniklinikum Salzburg; Merz; Teva ratiopharm.\u00a0\u2013 Advisory Boards\/Expertenmeetings: Allergan; Gr\u00fcnenthal; Eli Lilly; Lundbeck; Merck; Novartis; Pfizer; Springer Verlag; Stada; Teva ratiopharm.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellt als leitender Oberarzt, Universit\u00e4tsklinik f\u00fcr Neurologie, PMU Salzburg, Mitgliedschaften: Deutsche Schmerzgesellschaft (DGSS); European Academy of Neurology (EAN), Member of the Scientific Panel Pain; \u00d6GN; \u00d6sterreichische Kopfschmerzgesellschaft (\u00d6KSG), Vizepr\u00e4sident; \u00d6SG, Vorstandsmitglied.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}